These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2922918)

  • 1. Withdrawal of mitotane.
    Macholc EJ
    Vet Rec; 1989 Feb; 124(7):177. PubMed ID: 2922918
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of mitotane on the hypoprothrombinemic effect of warfarin.
    Cuddy PG; Loftus LS
    South Med J; 1986 Mar; 79(3):387-8. PubMed ID: 3952554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitotane for adrenocortical carcinoma treatment.
    Hahner S; Fassnacht M
    Curr Opin Investig Drugs; 2005 Apr; 6(4):386-94. PubMed ID: 15898346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
    Germano A; Saba L; De Francia S; Rapa I; Perotti P; Berruti A; Volante M; Terzolo M
    PLoS One; 2018; 13(5):e0196931. PubMed ID: 29734384
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new simple HPLC method for measuring mitotane and its two principal metabolites Tests in animals and mitotane-treated patients.
    De Francia S; Pirro E; Zappia F; De Martino F; Sprio AE; Daffara F; Terzolo M; Berruti A; Di Carlo F; Ghezzo F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Jun; 837(1-2):69-75. PubMed ID: 16698327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of mitotane therapy in dogs with pituitary dependent Cushing syndrome on the adrenal gland size--an ultrasonographic study].
    Hörauf A; Reusch C
    Schweiz Arch Tierheilkd; 1999; 141(5):239-45. PubMed ID: 10354742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained remission of Cushing's disease with mitotane and pituitary irradiation.
    Schteingart DE; Tsao HS; Taylor CI; McKenzie A; Victoria R; Therrien BA
    Ann Intern Med; 1980 May; 92(5):613-9. PubMed ID: 6247946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding mitotane mode of action.
    Waszut U; Szyszka P; Dworakowska D
    J Physiol Pharmacol; 2017 Feb; 68(1):13-26. PubMed ID: 28456766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane.
    D'Avolio A; De Francia S; Basile V; Cusato J; De Martino F; Pirro E; Piccione F; Ardito A; Zaggia B; Volante M; Di Perri G; Terzolo M
    Pharmacogenet Genomics; 2013 Jun; 23(6):293-300. PubMed ID: 23524664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological adrenalectomy with mitotane.
    Breuner CW; Jennings DH; Moore MC; Orchinik M
    Gen Comp Endocrinol; 2000 Oct; 120(1):27-34. PubMed ID: 11042008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.
    Villa R; Orlandi L; Berruti A; Dogliotti L; Zaffaroni N
    Int J Oncol; 1999 Jan; 14(1):133-8. PubMed ID: 9863019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic activity of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (mitotane) and its analogs on feminizing adrenal neoplastic cells in culture.
    Fang VS
    Cancer Res; 1979 Jan; 39(1):139-45. PubMed ID: 761184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of erythrocyte cell membrane scrambling by mitotane.
    Jacobi J; Lang E; Bissinger R; Frauenfeld L; Modicano P; Faggio C; Abed M; Lang F
    Cell Physiol Biochem; 2014; 33(5):1516-26. PubMed ID: 24854840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of dissolution rate of mitotane and warfarin prepared by using microemulsion systems.
    Lin YH; Chen YS; Wu TC; Chen LJ
    Colloids Surf B Biointerfaces; 2011 Jul; 85(2):366-72. PubMed ID: 21478000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mitotane as possible cause of acute intermittent porphyria].
    von Eyben FE
    Ugeskr Laeger; 2011 Sep; 173(37):2268-9. PubMed ID: 21917227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjunctive treatment of adrenocortical carcinoma.
    Terzolo M; Berruti A
    Curr Opin Endocrinol Diabetes Obes; 2008 Jun; 15(3):221-6. PubMed ID: 18438168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral and vulvo-vaginal lichenoid reactions due to mitotane (Lysodren): A case report.
    Schmouchkovitch A; Herry H; Thuillier P; Kerlan V; Fleuret C; Le Toux G; Boisramé S
    Medicine (Baltimore); 2017 Jan; 96(2):e5075. PubMed ID: 28079787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of mitotane on gene expression in the adrenocortical cell line NCI-H295R: a microarray study.
    Zsippai A; Szabó DR; Tömböl Z; Szabó PM; Eder K; Pállinger E; Gaillard RC; Patócs A; Tóth S; Falus A; Rácz K; Igaz P
    Pharmacogenomics; 2012 Sep; 13(12):1351-61. PubMed ID: 22966885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic drug monitoring of mitotane: Analytical assay and patient follow-up.
    Feliu C; Cazaubon Y; Guillemin H; Vautier D; Oget O; Millart H; Gozalo C; Djerada Z
    Biomed Chromatogr; 2017 Nov; 31(11):. PubMed ID: 28432798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of radiation damage in rat spinal cord by mitotane.
    Glicksman AS; Bliven SF; Leith JT
    Cancer Treat Rep; 1982 Jul; 66(7):1545-7. PubMed ID: 7093970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.